
Ozempic injection
Semaglutide · Off-label for weight management
Injectable · Off-label for weight management.
- Administration
- Weekly injection
- Clinical evaluation
- Required before prescribing
- Membership
- $109/month · Medication billed separately
Availability and suitability depend on individual evaluation. Membership does not guarantee a prescription.
Understanding Ozempic injection
Ozempic is an FDA-approved semaglutide medicine for specified type 2 diabetes-related indications. It is not FDA-approved for weight management. Its use for weight management is off-label and requires a careful clinical discussion.
How it works
Semaglutide activates GLP-1 receptors, helping regulate insulin release, glucagon and appetite. Shared ingredients do not make Ozempic and Wegovy interchangeable; their approved uses and dosing differ.
How it is administered
Ozempic is injected under the skin once weekly, with clinician-directed dose escalation and device-specific instructions. Never share pens or substitute another semaglutide product without clinical guidance.
Clinical research & results
Ozempic trials studied populations and doses relevant to its approved indications. The Wegovy 14.9% figure is not an Ozempic result and is not used here. No weight-loss calculator is assigned to this off-label offering.
These are separate trials, not a direct comparison between medicines. Study averages do not establish which medicine is best for you.
Ozempic full prescribing informationCommon side effects
Nausea, vomiting, diarrhea, abdominal pain and constipation are common. Persistent symptoms require a review of hydration, dose and treatment suitability.
Safety & important considerations
- Do not use with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a serious allergy to the medication. These products carry a boxed thyroid C-cell tumor warning; the risk in humans is unknown.
- Serious risks include pancreatitis, gallbladder problems, dehydration-related kidney injury and severe digestive symptoms. These medicines are not recommended in severe gastroparesis. Seek urgent care for persistent severe abdominal pain, serious allergic symptoms, or sudden vision changes.
- Tell your clinician about all medicines, diabetes-related eye disease, planned anesthesia or deep sedation, and pregnancy plans. Low blood sugar risk can increase with insulin or sulfonylureas. Do not combine with other GLP-1 medicines; your clinician reviews interactions and suitability.
- Stop semaglutide at least 2 months before a planned pregnancy with clinical guidance. Discuss the off-label nature of weight-management use, alternative approved treatments and diabetes-related eye risks before treatment.
This is a summary, not a complete list of risks or instructions. Read the full prescribing information and Medication Guide and speak with your clinician.
Read official safety informationMore about Ozempic injection
Is Ozempic approved for weight loss?
No. Weight-management use is off-label. A clinician must explain the rationale, risks and approved alternatives.
Why is there no calculator here?
The specified Wegovy trial studied Wegovy at its own dose, not Ozempic. Applying that percentage to Ozempic would misrepresent the evidence.
Can I switch between Ozempic and Wegovy myself?
No. Your prescriber must plan any change and account for doses, timing, your health history and other medicines.